Navtemadlin

DB15299InvestigationalSmall molecule

Navtemadlin (AMG-232) is under investigation in clinical trial NCT03041688 (MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia).

Chemical structure of Navtemadlin
Formula / weight
C28H35Cl2NO5S · 568.55 g/mol (avg)
Code names
AMG-232 · KRT-232 · MDM2 INHIBITOR AMG-232

Resolves to

Compound
UNII7R7G6EH5ULCAS1352066-68-2ChEMBLCHEMBL3125702
Structure
InChIKeyDRLCSJFKKILATL-YWCVFVGNSA-NSMILESCC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)C1=CC=CC(Cl)=C1)C1=CC=C(Cl)C=C1
Targets
Q00987MDM2

What you can answer from here — as of September 12, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
22Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Navtemadlin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In